American Society of Hirudotherapy

Reconstruction of intraoral defects after resection of cancer with two types of submental artery perforator flaps

Research article published in The British journal of oral & maxillofacial surgery (2018)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportClinical TrialsHuang et al. · The British journal of oral & maxillofacial surgery, 2018

Abstract

The submental island flap is a common choice for reconstruction of intraoral defects. To obtain a thinner, more pliable flap and get a better oncological result, the submental artery perforator flap has been proposed, and to assess its feasibility for closure of defects after resection of cancers of the oral cavity we studied 20 patients, each of whom was treated in this way. All the flaps were classified into those with septocutaneous perforators (n=16) and those with musculocutaneous perforators (n=4), and the main veins that drained the flaps were two submental veins (n=17). There were two patterns of venous drainage: in pattern 1 (n=9) the external jugular vein provided the primary venous drainage, and in pattern 2, the submental veins drained mainly into the facial vein, the common facial vein, and the internal jugular (n=10). In one patient the submental veins bypassed the facial vein to drain into the internal jugular. Eighteen of the 20 patients had no postoperative complications. The remaining two developed mild venous congestion of the flaps, which was resolved with conservative management and no skin loss. No local or regional recurrence was detected after a mean (range) follow-up of 21 (4-35) months. This is a simple, reliable flap that can be used for the reconstruction of intraoral defects after resections for cancer, but its oncological outcome still requires proof in long-term, large-scale, clinical trials.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAdultAgedArteriesFemaleHumansMaleMiddle AgedMouthMouth FloorMouth NeoplasmsMyocutaneous FlapPerforator Flap

Summary

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Why This Matters for Hirudotherapy

This case series of 20 patients examined two types of submental artery perforator flaps for reconstructing intraoral defects after oral-cavity cancer resection, mapping the flaps' venous drainage patterns and reporting that 18 of 20 patients had no postoperative complications while 2 developed mild venous congestion that resolved with conservative management and no skin loss. The relevance to hirudotherapy lies in its careful attention to flap venous drainage anatomy and the appearance of venous congestion, the specific complication the medicinal leech is used to relieve when a flap's outflow is compromised. This is a small single-arm case series in which the congestion resolved conservatively without leech therapy, so it illustrates the clinical setting rather than providing evidence for or against leeching, and the authors themselves note the oncological outcome still requires larger long-term study.

Citation

Reconstruction of intraoral defects after resection of cancer with two types of submental artery perforator flaps.

Huang et al. · The British journal of oral & maxillofacial surgery, 2018

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.